CJC-1295 with DAC Research Peptide | Biovantage Labs

CJC-1295 with DAC Research Peptide | Biovantage Labs

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analogue incorporating a Drug Affinity Complex that extends plasma half-life through covalent albumin binding. It is studied for its sustained stimulation of pituitary growth hormone secretion in preclinical research models. Biovantage Labs supplies CJC-1295 with DAC at 99+% purity, HPLC/MS verified. Domestically fulfilled from Canada. Not for human consumption.

$70.00

Description

CJC-1295 with DAC Biovantage Labs Research Peptide

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analogue incorporating a Drug Affinity Complex that extends plasma half-life through covalent albumin binding. It is studied for its sustained stimulation of pituitary growth hormone secretion in preclinical research models. Biovantage Labs supplies CJC-1295 with DAC at 99+% purity, HPLC/MS verified. Domestically fulfilled from Canada. Not for human consumption. Biovantage Labs provides this compound at 99+% purity, confirmed by batch-specific HPLC and Mass Spectrometry analysis, as a lyophilized compound for use in controlled laboratory settings.

Molecular Profile and Chemical Specifications

Specification Detail
Molecular Formula C165H271N47O46
Molecular Weight 3,647.1 Da
Modification DAC (Drug Affinity Complex). Lys residue conjugation for albumin binding
Purity ≥99+% (HPLC/MS verified)
Physical Form Lyophilized white powder
CAS Number 863288-34-0

 

Primary Research Mechanisms

GHRH Receptor Agonism and GH Pulse Amplification

CJC-1295 with DAC binds and activates the growth hormone releasing hormone receptor (GHRHR) on pituitary somatotrophs. Research examines its capacity to amplify the amplitude of endogenous GH pulses rather than eliminating the natural pulsatile release pattern entirely.

CJC-1295 with DAC is most frequently studied alongside Ipamorelin in dual-agonist research protocols. CJC-1295 targets the GHRH receptor while Ipamorelin targets GHS-R1a, providing simultaneous stimulation of both upstream GH secretagogue pathways for research examining synergistic GH pulse amplification.

Albumin Binding via DAC Modification

The Drug Affinity Complex modification enables reversible covalent binding to plasma albumin, extending the functional half-life from minutes (native GHRH) to several days. This extended activity window is the primary pharmacokinetic property under investigation in half-life extension research.

IGF-1 Axis Modulation

As a downstream consequence of sustained GH stimulation, CJC-1295 with DAC is studied for its effects on circulating and tissue-level IGF-1 expression in animal models, representing a secondary axis of investigation in GH research protocols.

Researchers comparing GHRH analogue pharmacokinetic profiles may also examine Tesamorelin, a stabilized GHRH analogue with DPP-IV resistance achieved through a different structural modification than the DAC conjugation employed in CJC-1295.

Reconstitution Protocol

  •       Reconstitute using sterile bacteriostatic water or 0.9% sodium chloride solution
  •       Introduce diluent slowly along the interior vial wall do not inject directly onto the lyophilized cake
  •       Swirl gently until fully dissolved do not shake or vortex
  •       Allow the vial to equilibrate to room temperature before opening to prevent condensation

Storage and Stability

Storage Condition State Estimated Stability
-20°C to -80°C Lyophilized 24+ months
2°C to 8°C Lyophilized 12 months
Room temperature (20°C) Lyophilized 3 months
2°C to 8°C Reconstituted 7 to 14 days

 

Store in a desiccated environment away from UV exposure. Avoid repeated freeze-thaw cycles, which degrade peptide chain integrity over time.

CJC-1295 with DAC Research FAQ

Q: How does CJC-1295 with DAC differ from CJC-1295 without DAC?

A: CJC-1295 without DAC (sometimes referred to as Modified GRF 1-29) has a half-life of approximately 30 minutes in preclinical models. The DAC conjugation in CJC-1295 with DAC extends this to an estimated 6 to 8 days by enabling reversible albumin binding. These represent different pharmacokinetic profiles suited to different research protocol designs.

Q: Is CJC-1295 with DAC for human use?

A: No. CJC-1295 with DAC supplied by Biovantage Labs is strictly for laboratory research purposes. It is not approved for human consumption, veterinary use, or clinical application.

Q: What purity standard does Biovantage Labs apply?

A: Every batch is verified at 99+% purity using HPLC to confirm compound concentration and Mass Spectrometry to confirm molecular identity. Batch-specific COA documentation is available upon request.

Q: Where does Biovantage Labs ship from?

A: All Biovantage Labs products are fulfilled domestically from within Canada, eliminating customs clearance risk and reducing transit time compared to international suppliers.

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 with DAC Research Peptide | Biovantage Labs”

Your email address will not be published. Required fields are marked *

Related Products

High Quality Research Peptides You Can Trust

Explore premium-grade peptides for scientific research, purity tested, lab certified, and shipped discreetly.